Skip to search formSkip to main contentSkip to account menu

ranolazine

Known as: Renolazine, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy- 3-(2-methoxyphenoxy)propyl)-, Ranolazine [Chemical/Ingredient] 
An orally available, piperazine derivative with anti-anginal and potential antineoplastic activities. Ranolazine's mechanism of action for its anti… 
National Institutes of Health

Related topics

Related topics

17 relations
12 HR ranolazine 500 MG Extended Release Oral Tablet [Ranexa]Angina PectorisAntianginalsIn Blood

Broader (2)

Cardiovascular AgentsSodium Channel Blockers

Narrower (3)

RS 43285RS 43285-193Ranexa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The Antianginal Agent Ranolazine Inhibits Mitochondrial ò-OxidationPathway
Abstract Backgrounds: Ranolazine had two main functions: blocking cardiac late sodium channels and / or inhibition of 3- ketoacyl… 
2015
2015
Application of Ranolazine in Stable Angina Pectoris Therapy (ARETHA): Real-World Data from an Observational Study
Objective: Ranolazine, a late sodium current inhibitor, is indicated in adults as add-on therapy for the symptomatic treatment of… 
Review
2015
Review
2015
Ranolazine: Beyond the Treatment of Chronic Stable Angina Pectoris
The aims in the treatment of angina are relief of pain and prevention of disease progression through risk reduction. A number of… 
2013
2013
Optimization of Formulation Variables of Ranolazine Extended-Release Tablets by 3 2 Full Factorial Design
Ranolazine is antianginal drug, approved by US FDA in 2006. It is marketed as extended release tablets (Ranexa 500mg/1gm… 
2013
2013
New ESC guidelines published on stable coronary artery disease.
The ‘ESC Guidelines on the management of stable coronary artery disease’ were presented for the first time at the ESC Congress by… 
2011
2011
Development of Sustain Release Matrix Tablet of Ranolazine Based on Methocel K4M CR: In Vitro Drug Release and Kinetic Approach
This article was published in the Journal of Applied Pharmaceutical Science [© 2011 Journal of Applied Pharmaceutical Science] 
2011
2011
DEVELOPMENT OF RAPID VISIBLE SPECTROPHOTOMETRIC METHODS FOR THE ESTIMATION OF RANOLAZINE IN FORMULATIONS
Simple, sensitive, accurate, precise and rapid Visible Spectrophotometric methods were developed for the estimation of Ranolazine… 
Review
2005
Review
2005
Ranolazine: An update on the novel antianginal agent
Ranolazine (Ranexa, CV Therapeutics) is a partial fatty acid oxidase inhibitor that increases the amount of ATP produced from… 
2003
2003
Gender difference in ranolazine pharmacokinetics in rats
SummaryPharmacokinetics of ranolazine(RAN) in both female and male rats was studied. RAN concentrations in plasma were determined… 
2003
2003
Ranolazine: A novel metabolic modulator for the treatment of chronic stable angina
Current medical therapy for chronic stable angina (CSA) is targeted at reducing the frequency of anginal symptoms and improving…